Back to top
more

Ionis Pharmaceuticals (IONS)

(Delayed Data from NSDQ)

$39.19 USD

39.19
1,019,400

+0.73 (1.90%)

Updated Nov 8, 2024 03:59 PM ET

After-Market: $39.21 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Avita Medical Inc. (RCEL) Stock Jumps 6.2%: Will It Continue to Soar?

by Zacks Equity Research

Avita Medical Inc. (RCEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Biogen (BIIB) Inks Licensing Deal for Implantable Medical Device

by Zacks Equity Research

Biogen (BIIB) signs a license and collaboration agreement with Alcyone Therapeutics to develop the latter's ThecaFlex DRx system to get access to neurological antisense oligonucleotide therapies.

Why Is Ionis Pharmaceuticals (IONS) Down 16.4% Since Last Earnings Report?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam (ALNY) Seeks to Expand Onpattro Label in Cardiomyopathy

by Zacks Equity Research

Alnylam (ALNY) initiates label expansion filing with FDA for Onpattro to treat cardiomyopathy in patients suffering from ATTR-amyloidosis. The drug is already approved to treat polyneuropathy in such patients.

Biogen's (BIIB) ALS Drug Tofersen Filing Accepted in Europe

by Zacks Equity Research

Biogen's (BIIB) tofersen, if approved, will be the first genetically-targeted treatment for SOD1-ALS in Europe.

InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program

by Zacks Equity Research

InMed Pharmaceuticals (INM) surges on receiving research grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to investigate its cannabinoid drug candidates.

Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines

by Zacks Equity Research

Ionis (IONS) inks collaboration deal with the gene editing company, Metagenomi, to expand the former's capabilities in delivering precision genetic medicines.

FDA Accepts Amneal's (AMRX) Parkinson's Candidate NDA For Review

by Zacks Equity Research

Amneal Pharmaceuticals' (AMRX) shares rise after the company announces that its Parkinson's candidate IPX203 NDA has been accepted for review by the FDA.

Ionis (IONS) Q3 Earnings & Sales Beat Estimates, Stock Up

by Zacks Equity Research

Ionis (IONS) incurs a narrower-than-expected loss in Q3. Its sales also beat estimates.

Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 55.41% and 7.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Ionis (IONS) This Earnings Season?

by Zacks Equity Research

Ionis (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Earnings Preview: Scynexis (SCYX) Q3 Earnings Expected to Decline

by Zacks Equity Research

Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cassava Sciences (SAVA) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Cassava Sciences (SAVA) is expected to provide an update on its pipeline candidates during its third-quarter earnings.

Zoetis (ZTS) to Report Q3 Earnings: Is a Beat in Store?

by Zacks Equity Research

Zoetis (ZTS) is anticipated to report positive earnings and revenues for third-quarter 2022. It will also provide an update on its pipeline on the earnings call.

Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biogen's (BIIB) FDA Filing for ALS Drug Gets 3 Months Extension

by Zacks Equity Research

The FDA extends the review period for Biogen's (BIIB) NDA for tofersen in SOD1-ALS. This extension is due to BIIB's submission of additional data, constituting a major amendment to the earlier filing.

Biohaven Pharma's (BHVN) ALS Study Fail to Meet Both Endpoints

by Zacks Equity Research

Biohaven Pharmaceuticals (BHVN) suffers a setback as verdiperstat fails to meet the primary and secondary endpoints in an ALS study.

Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's Updates

by Zacks Equity Research

Regulatory and pipeline updates from BIIB and IONS are the key highlights from the biotech sector during the past week.

Ionis' (IONS) Hypercholesterolemia Drug Not to Enter Phase III

by Zacks Equity Research

Ionis (IONS) posts data from the phase IIb SOLANO study on ION449 for treating hypercholesterolemia. Though the study met the primary endpoint, ION449 will not advance into phase III development.

Strength Seen in Esperion Therapeutics (ESPR): Can Its 5.7% Jump Turn into More Strength?

by Zacks Equity Research

Esperion Therapeutics (ESPR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down

by Zacks Equity Research

Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.

Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -21.31% and 9.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

The Zacks Analyst Blog Highlights Take-Two Interactive Software, Ionis Pharmaceuticals, Celsius Holdings, Grocery Outlet Holding and Lemonade

by Zacks Equity Research

Take-Two Interactive Software, Ionis Pharmaceuticals, Celsius Holdings, Grocery Outlet Holding and Lemonade are part of Zacks top Analyst Blog.

Why Ionis Pharmaceuticals (IONS) Might Surprise This Earnings Season

by Zacks Equity Research

Ionis Pharmaceuticals (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.